Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Imunon, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IMNN
Nasdaq
2830
imunon.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Imunon, Inc.
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
- Feb 10th, 2025 1:05 pm
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…
- Jan 28th, 2025 2:10 pm
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
- Dec 19th, 2024 1:05 pm
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
- Dec 10th, 2024 1:05 pm
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…
- Nov 25th, 2024 2:30 pm
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
- Nov 25th, 2024 1:05 pm
IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial
- Nov 11th, 2024 10:00 am
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...
- Nov 8th, 2024 7:23 am
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
- Nov 7th, 2024 3:00 pm
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Nov 7th, 2024 1:05 pm
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
- Oct 31st, 2024 12:30 pm
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
- Oct 30th, 2024 1:05 pm
Imunon reports inducement grant under NASDAQ listing rule
- Oct 8th, 2024 12:45 pm
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Oct 7th, 2024 12:05 pm
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
- Sep 9th, 2024 8:06 pm
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
- Sep 9th, 2024 12:30 pm
IMUNON to Host R&D Day on September 18th
- Aug 28th, 2024 12:30 pm
IMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study…
- Aug 15th, 2024 3:28 pm
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Aug 14th, 2024 12:00 pm
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
- Aug 7th, 2024 9:04 pm
Scroll